All Escherichia coli Nissle 1917 articles
-
NewsInvisible smart bug fights gum disease
Current treatments for periodontitis often fail because they cannot simultaneously eliminate stubborn bacterial biofilms and calm the runaway inflammation that follows. Now researchers have engineered a living bacterium that does both, in the right order.
-
NewsEngineered bacteria deliver cancer drug directly inside tumors in mice
New research suggests that Escherichia coli Nissle 1917 (EcN) may be engineered with anticancer agents to treat cancerous tumors in mice. Researchers used EcN as a base for synthesizing Romidepsin (FK228), an FDA-approved drug with anti-tumor agents.
-
NewsNext-generation microbiome medicine may revolutionize the treatment of Parkinson’s and similar disorders
Scientists have engineered the probiotic bacterium Escherichia coli Nissle 1917 as a drug-delivery system that continuously produces and delivers the gold-standard Parkinson’s drug Levodopa, which is converted to dopamine in the brain. E. coli Nissle strain was chosen for its century-long record of safely treating gastrointestinal disorders in humans.
-
NewsStudy reveals a way to protect microbes from extreme conditions
By helping microbes withstand industrial processing, the method could make it easier to harness the benefits of microorganisms used as medicines and in agriculture.
-
NewsCocktails of antibiotics, probiotics and prebiotics hold promise in treating a common form of irritable bowel syndrome
Personalised “cocktails” of antibiotics, probiotics and prebiotics hold great promise in the treatment of a common form of irritable bowel syndrome (IBS), a new study suggests.